Merci, madame Brunelle.
Members, we have about 13 minutes. I have a couple of questions, and I have the next spot.
I'm not going to hold members here. I know they have to get to the House. But for the witnesses, if you wouldn't mind staying for a few more minutes, I will add my questions, and if we have time, we can get in a couple of more questions as well.
First of all, I want to follow up on Madame Brunelle's discussion with Ms. Perkins and Mr. Elliott with respect to the schedules.
You're correct in the sense that we do not have to have the schedules in the legislation. In fact, I think other countries do not have schedules in their legislation. But when I asked this of the Industry Canada representative, he said that if we don't have schedules in the legislation, it will in fact make the process longer because litigation over the patents will result. So it was Industry Canada's view that if you had the schedules and you had the identified pharmaceuticals, you'd actually make the process simpler.
I want to get your response to that statement.